Furthermore, IFN-λ3 also showed antitumor activity in murine models of cancer, including hepatoma.[46] Our results also found that ADV can obtain good outcomes in 1-, 3-, 5-year recurrence-free survival (64.7%, 64.7%, 70.4%), which is consistent with previous studies. Here, IFNL3 is linked to hepatocellular carcinoma.